Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
What if I'm afraid of needles
The answer from the data is clear: do not
Real Patient Success Stories from Murphy & Plano While I cant share specific patient details, I can tell you that Ive seen remarkable transformations
Remember, the goal isnt simply losing weight, but supporting your body so that metabolic health improves along the way
Repurposing GLP-1 receptor agonists and novel dual/triple GLP-1, GIP, and glucagon agonists represent promising therapeutic strategies that have shown to be effective in targeting inflammation, tau phosphorylation, synaptic dysfunction, insulin resistance, and oxidative stress
